Comparing Flex Pharma (FLKS) and Kitov Pharmaceuticals Holdings (KTOV)

Flex Pharma (NASDAQ: FLKS) and Kitov Pharmaceuticals Holdings (NASDAQ:KTOV) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, valuation, dividends, profitability and analyst recommendations.

Profitability

This table compares Flex Pharma and Kitov Pharmaceuticals Holdings’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Flex Pharma -2,655.19% -71.39% -65.49%
Kitov Pharmaceuticals Holdings N/A N/A N/A

Insider and Institutional Ownership

28.1% of Flex Pharma shares are owned by institutional investors. Comparatively, 5.0% of Kitov Pharmaceuticals Holdings shares are owned by institutional investors. 45.4% of Flex Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Flex Pharma and Kitov Pharmaceuticals Holdings’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Flex Pharma $1.01 million 67.43 -$39.49 million ($2.02) -1.88
Kitov Pharmaceuticals Holdings N/A N/A -$12.12 million N/A N/A

Kitov Pharmaceuticals Holdings has higher revenue, but lower earnings than Flex Pharma.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Flex Pharma and Kitov Pharmaceuticals Holdings, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Flex Pharma 0 1 3 0 2.75
Kitov Pharmaceuticals Holdings 0 0 0 0 N/A

Flex Pharma presently has a consensus target price of $11.00, indicating a potential upside of 190.24%. Given Flex Pharma’s higher possible upside, analysts plainly believe Flex Pharma is more favorable than Kitov Pharmaceuticals Holdings.

Risk & Volatility

Flex Pharma has a beta of 3.19, suggesting that its stock price is 219% more volatile than the S&P 500. Comparatively, Kitov Pharmaceuticals Holdings has a beta of 3.01, suggesting that its stock price is 201% more volatile than the S&P 500.

Summary

Flex Pharma beats Kitov Pharmaceuticals Holdings on 6 of the 10 factors compared between the two stocks.

About Flex Pharma

Flex Pharma, Inc. is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms. The Company operates through developing and commercializing products for nocturnal leg cramps, muscle cramps, spasms and spasticity associated with severe neuromuscular conditions, and exercise-associated muscle cramps segment. The Company’s lead drug product candidate is FLX-787, which is in the Phase II clinical trial stage. It is developing a consumer brand and products specifically formulated to treat athletes suffering from EAMCs.

About Kitov Pharmaceuticals Holdings

Kitov Pharmaceuticals Holdings Ltd is an Israel-based company that develops non-steroidal anti-inflammatory drugs that treat pain without raising blood pressure, thus avoiding the increased risk of heart attacks, strokes or death.

Receive News & Ratings for Flex Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flex Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply